益生元补充对接受化疗的不同原发肿瘤部位结直肠癌患者肠道菌群、药物生物利用度及不良反应的影响:随机临床试验研究方案
本研究为双盲、随机、平行对照临床试验,拟纳入左半结直肠癌(LSCRC,n=50)和右半结肠癌(RSCC,n=50)患者,随机分入益生元组(n=25)或对照组(n=25),分别每日接受低聚木糖(XOS)3 g或安慰剂,持续12周。主要结局为不同肿瘤部位黏膜菌群组成差异及治疗后肠道菌群组成、不良反应和卡培他滨血药浓度差异。
要点
- 双盲随机对照试验,比较XOS 3 g/日与安慰剂12周对左半与右半结直肠癌化疗患者的影响。
- 主要结局包括不同肿瘤部位黏膜菌群差异及治疗后菌群、不良反应和卡培他滨血药浓度。
- 次要结局包括其他血液指标、短链脂肪酸浓度、生活质量和心理健康。
核心结论
- 本研究旨在揭示益生元改善肠道菌群组成、减轻不良反应和提高结直肠癌患者化疗疗效的潜在获益。
- 研究将提供左半结直肠癌与右半结肠癌肿瘤菌群分布差异及治疗期间肠道菌群变化的数据,可能为未来基于原发肿瘤部位和肠道菌群的个性化癌症治疗策略提供新见解。
研究设计与样本
- 双盲、随机、平行对照临床试验。
- 拟纳入左半结直肠癌(LSCRC,n=50)和右半结肠癌(RSCC,n=50)患者,随机分入益生元组(n=25)或对照组(n=25)。
主要发现
- 益生元组每日接受低聚木糖(XOS)3 g,对照组接受安慰剂,持续12周。
- 主要结局为不同肿瘤部位黏膜菌群组成差异及治疗后肠道菌群组成、不良反应和卡培他滨血药浓度差异。
- 次要结局包括其他血液指标、短链脂肪酸(SCFAs)浓度、生活质量和心理健康。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevalence of colorectal cancer (CRC) worldwide is a huge challenge to human health. Primary tumor locations found to impact prognosis and response to therapy. The important role of gut microbiota in the progression and treatment of CRC has led to many attempts of alleviating chemotherapy-induced adverse effects using microecologics. However, the underlying mechanism of the difference in the prognosis of different primary tumor locations and the synergistic effect of prebiotics on chemotherapy need to be further elucidated. This study aims to explore the differences in tumor microbiota and examine the effectiveness of xylooligosaccharides (XOS) on gut microbiota, adverse effects, and bioavailability of chemotherapy drugs in CRC patients at different primary tumor locations. METHODS: This is a double-blinded, randomized, parallel controlled clinical trial. Participants with left-sided CRC (LSCRC, n = 50) and right-sided CC (RSCC, n = 50) will randomly allocated to prebiotic group (n = 25) or control group (n = 25) and will receive either a daily XOS (3 g/day) or placebo, respectively, for 12 weeks. The primary outcomes will be the differences in the mucosa microbiota composition at different tumor locations and differences in gut microbiota composition, adverse effects, and blood concentration of capecitabine posttreatment. The secondary outcomes will include other blood indicators, short-chain fatty acids (SCFAs) concentration, quality of life, and mental health. DISCUSSION: This study will reveal the potential benefits of prebiotic for improving the gut microbiota composition, alleviating the adverse effects, and improving the efficacy of chemotherapy in patients with CRC. In addition, this study will provide data on the different distribution of tumor microbiota and the different changes of gut microbiota during treatment in LSCRC and RSCC, which may provide novel insights into personalized cancer treatment strategies based on primary tumor locations and gut microbiota in the future. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( www.chictr.org.cn ): ChiCTR2100046237. Registered on 12 May 2021.
引用
- Chen Y, Liao X, Li Y, et al. Effects of prebiotic supplement on gut microbiota, drug bioavailability, and adverse effects in patients with colorectal cancer at different primary tumor locations receiving chemotherapy: study protocol for a randomized clinical trial. Trials. 2023. PMID: 37046334. doi:10.1186/s13063-023-07137-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。